Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06821542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06821542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 4, 2025
Completion date
November 30, 2032
Enrollment
9 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease